Which is more profitable, Eli Lilly or Merck KGaA?

Eli Lilly keeps more of every sale as profit.

Which grows faster, Eli Lilly or Merck KGaA?

Eli Lilly grew its sales faster in recent years.

Which is cheaper, Eli Lilly or Merck KGaA?

Merck KGaA costs less for each unit of yearly profit (lower P/E).

Which has less debt, Eli Lilly or Merck KGaA?

Eli Lilly would need fewer years of earnings to pay off its debt.

Eli LillyLLYvs

Merck KGaAMRK.DE

Eli Lilly vs Merck KGaA stock

Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.

In one sentence

Eli Lilly is more profitable, grows faster and has less debt. Merck KGaA is cheaper for its profits.

Side by side

	Eli Lilly	Merck KGaA
	$1.29 trillion	€65.0 billion
	31.7%	12.4%
	+21.6%	−1.7%
	62.3×	24.9×
	1.1 years	1.6 years
	34.8%	6.4%
	0.6%	0.4%

Open Eli Lilly Open Merck KGaA

How we compare

Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.

More comparisons: Eli Lilly vs Moderna · Eli Lilly vs Natera · Eli Lilly vs Novo Nordisk · Eli Lilly vs Novartis · Merck KGaA vs Merck & · Merck KGaA vs Roche · Merck KGaA vs AbbVie · Merck KGaA vs Johnson & Johnson